Gabica Special Precautions

Withdrawal of Antiepileptic Drugs (AEDs): As with all AEDs, pregabalin should be withdrawn gradually to minimize the potential of increased seizure frequency in patients with seizure disorders. If pregabalin is discontinued this should be done gradually over a minimum of 1 week.
Angioedema: Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral or upper airway swelling occur.
Weight Gain: Pregabalin associated weight gain is related to dose and duration of exposure. Some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycemic medications.
Discontinuation: After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following events have been mentioned: insomnia, headache, nausea and diarrhea, flu syndrome, nervousness, depression, pain, sweating and dizziness.
Creatinine Kinase Elevation: Pregabalin should be discontinued if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.
Congestive Heart Failure: There have been reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.
Alcohol: Patients should be told to avoid consuming alcohol while on pregabalin, as it may potentiate the impairment of motor skills and sedation of alcohol.
Effects on Ability to Drive and Use Machines and Injuries: Pregabalin may cause dizziness and somnolence and therefore may have an influence on the ability to drive or use machines or may increase the occurrence of accidental injuries especially in the elderly population.
Use in Pregnancy & Lactation: See USE IN PREGNANCY & LACTATION section for further information.
Use in Children: Pregabalin is not recommended for use in children below the age of 12 years and adolescents (12-17 years) due to insufficient data on safety and efficacy.